Stock comparison
Regencell Bioscience Holdings Limited
ResMed
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
RGC
Regencell Bioscience Holdings Limited
Market cap
$12.76B
Sector
Healthcare
RMD
ResMed
Market cap
$30.18B
Sector
Healthcare
Overall winner
ResMed RMD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | RGC | RMD | Winner |
|---|---|---|---|
| Warren Buffett | 29F | 72B | RMD |
| Benjamin Graham | 16F | 75B | RMD |
| Philip Fisher | 43D | 75B | RMD |
| Peter Lynch | 17F | 58C | RMD |
| Joel Greenblatt | 2F | 47D | RMD |
| Charlie Munger | 40D | 69B | RMD |
| Terry Smith | 44D | 73B | RMD |
Side-by-side metrics
| Metric | RGC | RMD |
|---|---|---|
| Market cap | $12.76B | $30.18B |
| P/E (TTM) | - | 19.6x |
| EV/EBIT | - | 17.1x |
| ROIC (TTM) | -4.44% | 19.63% |
| Gross margin | 0.0% | 61.69% |
| Net margin | 0.0% | 27.44% |
| Revenue CAGR 5y | - | 12.64% |
| EPS CAGR 5y | - | 30.73% |
| Debt / Equity | 0.3x | 0.1x |
| Dividend yield | 0.0% | 1.14% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
RGC leads on
- P/E (TTM)-vs 19.6x+101%
- EV/EBIT-vs 17.1x+100%
RMD leads on
- ROIC (TTM)19.63%vs -4.44%+104%
- Gross margin61.69%vs 0.0%+100%
- Net margin27.44%vs 0.0%+100%
- Dividend yield1.14%vs 0.0%+100%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.